{"name":"EuBiologics Co.,Ltd","slug":"eubiologics-co-ltd","ticker":"","exchange":"","domain":"eubiologics.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"EuTCV","genericName":"EuTCV","slug":"eutcv","indication":"Other","status":"phase_1"},{"name":"ATGC-100","genericName":"ATGC-100","slug":"atgc-100","indication":"Other","status":"phase_1"},{"name":"Euvichol","genericName":"Euvichol","slug":"euvichol","indication":"Other","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"neuroscience","drugs":[{"name":"ChAdOx1 nCoV-19","genericName":"ChAdOx1 nCoV-19","slug":"chadox1-ncov-19","indication":"COVID-19 prevention in adults","status":"phase_3"},{"name":"EuCorVac-19","genericName":"EuCorVac-19","slug":"eucorvac-19","indication":"COVID-19 prevention in adults","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Botox 100U","genericName":"Botox 100U","slug":"botox-100u","indication":"Cervical dystonia","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"ATGC-100 100U","genericName":"ATGC-100 100U","slug":"atgc-100-100u","indication":"Thrombotic disorders or thromboembolism prevention (specific indication in Phase 3 not publicly detailed)","status":"phase_3"}]}],"pipeline":[{"name":"Botox 100U","genericName":"Botox 100U","slug":"botox-100u","phase":"phase_3","mechanism":"Botox (botulinum toxin type A) blocks acetylcholine release at the neuromuscular junction, causing temporary muscle paralysis.","indications":["Cervical dystonia","Blepharospasm","Hemifacial spasm","Strabismus","Chronic migraine"],"catalyst":""},{"name":"EuTCV","genericName":"EuTCV","slug":"eutcv","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ATGC-100","genericName":"ATGC-100","slug":"atgc-100","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ATGC-100 100U","genericName":"ATGC-100 100U","slug":"atgc-100-100u","phase":"phase_3","mechanism":"ATGC-100 is an antithrombin-based therapeutic that enhances natural anticoagulation pathways.","indications":["Thrombotic disorders or thromboembolism prevention (specific indication in Phase 3 not publicly detailed)"],"catalyst":""},{"name":"ChAdOx1 nCoV-19","genericName":"ChAdOx1 nCoV-19","slug":"chadox1-ncov-19","phase":"phase_3","mechanism":"ChAdOx1 nCoV-19 is a viral vector vaccine that delivers the SARS-CoV-2 spike protein gene into cells to trigger an immune response against COVID-19.","indications":["COVID-19 prevention in adults"],"catalyst":""},{"name":"EuCorVac-19","genericName":"EuCorVac-19","slug":"eucorvac-19","phase":"phase_3","mechanism":"EuCorVac-19 is a recombinant protein subunit vaccine that stimulates immune responses against SARS-CoV-2 by presenting viral spike protein antigens.","indications":["COVID-19 prevention in adults"],"catalyst":""},{"name":"Euvichol","genericName":"Euvichol","slug":"euvichol","phase":"phase_3","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipAJBVV95cUxQVWQxTDdWUnBzTFRkS0t4WDhMd08yQnpMekljN3ZqTnl3QjJwRU9nd05JY0lpRzZNMlNSa3Z3OGVLeFd2OVZIOFFaSm1sWUdWYXdaVTl4QVpDMG1lTFp5ajVuclFuU3JzNjdwUlNaeFFxSm9GSTVmcTdYaWZQS251akZEeGVUNmV6QVdvWm9JSThrdm5Id1JlblRRMUxPZTdDWVVuSXJId1p1a3ZhNlpwU0xCbEtIa2FhVHY4VDN0VEIwaUhab2otOUJ6RldaajNFTHZLZEtqTVNjNTRobDVkdm1DNklLbmhYbUZ0SDIyT1FtaTFyYlgwRUtXeVR0ZjhDLUptMEZpVV9DWE4ySFhtVWlDMDA4TF9LbHpvVmhjbWw3TkVl?oc=5","date":"2026-02-09","type":"pipeline","source":"PR Newswire UK","summary":"Invasive Fungal Infections Market to Witness Upsurge in Growth at a CAGR of 11.4% (in the US) During the Forecast Period (2025-2034) | DelveInsight - PR Newswire UK","headline":"Invasive Fungal Infections Market to Witness Upsurge in Growth at a CAGR of 11.4% (in the US) During the Forecast Period","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-04","type":"pipeline","source":"GlobeNewswire","summary":"Shingles Vaccine Research Report 2025: Market to Reach $9.6 - GlobeNewswire","headline":"Shingles Vaccine Research Report 2025: Market to Reach $9.6","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE5WaUtWWFkwSlNzbG1vNFpGUEh0R05GMFhWRWZnQWFrdDJwSkVxYWYwaDlCcWRUcl90QTlhMHV4OTZlWE9NaTlmci1OWUNTb3lkRnZwdWpLUkRvQmhmdkoySGV1akhZYVU?oc=5","date":"2025-03-05","type":"pipeline","source":"Market.us","summary":"Cholera Vaccines Market Size, Share Analysis | 9.3% CAGR - Market.us","headline":"Cholera Vaccines Market Size, Share Analysis | 9.3% CAGR","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1zdHM0dmhRSkNBUm1yQVNidjVTYnFHVXZvMThsQ3NkbTBoSVRranRScE9IcTcza0ZjLUR2QnhVM0prRm1Qb3ZyNHRMdDBqRnpfTXgyQ3hPY3IxLWsxT01kLVpUQ3J3RmZGN0VFQmVn0gFyQVVfeXFMTkIwT2FwbjktbG9iTnJhOGVQOTJLX3A3V3RwMWsxUHo1UHdEaENKcXI5RUhld3Y2d3ZpRHB4MVJCSWs3Y0stREo3RzhIU1R6aVVtRG14NG9tQmdFQUpGcFdfcXN1WDVBQzN0TFZiVXEwckJR?oc=5","date":"2024-07-31","type":"deal","source":"koreabiomed.com","summary":"EuBiologics inks deal with DEK to supply oral cholera vaccine’s raw material to Ghana - koreabiomed.com","headline":"EuBiologics inks deal with DEK to supply oral cholera vaccine’s raw material to Ghana","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE41ZlpWWEFkVmJCUl9vR1lrc0VjcWU2T0J3TmNDU1JaUi1YczJWcjQ2QjltcGIteV9hejB1V3YxcnZtRFNPUUtOVjVCUk84U3NoQnZLVm9WMUNJYUkzODBBLVdIYk51emlZQmtlRDBR0gFyQVVfeXFMTWE4dGxuVGhYZm1tOGZjaVAxZlhWSlFNTjZSd2h6bmdIRjVmZDVqTlJRYmV5cjh6b05wSmZzbHhJZ3UtcFNTbkpEdnY0eDdISnZ5bkZfTTJrMlVraWp1Q2dkNGcydXo0a3F1ZXBXcW5nand3?oc=5","date":"2024-07-03","type":"deal","source":"koreabiomed.com","summary":"EuBiologics license out EuMCV4 meningococcal vaccine to Eyegene - koreabiomed.com","headline":"EuBiologics license out EuMCV4 meningococcal vaccine to Eyegene","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxOaHNvSmstakZ2ZGMxRU4wOXVQMGtHOEduN3c1eGh3X192eG81cXh3aml2SGdoaVBuLW5oQ0JBd0N6UlNlNVpKbmZURUlFT1c3THh4VFVEQnJwSjVMZ0FieGkwTXJZMmJUNW1pRm1mN3FDd1lLNGV1eXhxSXdmUFFac1U4N3I0RFBY?oc=5","date":"2024-04-22","type":"pipeline","source":"조선일보","summary":"Praise pours in for Korean pharma firm, sole provider of cholera vaccine - 조선일보","headline":"Praise pours in for Korean pharma firm, sole provider of cholera vaccine - 조선일보","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQUHRRSTRHMW1BQUVodmk2dUVRWkpaOXhld1RYaTBPcE5zZUVpVHZBOGNZRjQyS2xwZExiV0lmcVM5NXpUZDBCeEtJWWlFR3NxVzFTVVBtcHRIZ2JsVjQtS3hpV0Z5cnVtTkZYWkhWVDB5TWx4Y3hHOXZ6c3VoVDl2R2JmbU1NMXEzT0VuaERYNEFUNDRMclNBQkNTcVQ3aW1zemhubUl3?oc=5","date":"2024-04-16","type":"pipeline","source":"BioWorld News","summary":"Eubiologics wins WHO prequalification for oral cholera vaccine - BioWorld News","headline":"Eubiologics wins WHO prequalification for oral cholera vaccine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxORXlJNnVZMjZwMVl2UktCel9YbTNvc1d0RXpYNHBRREtYam1OcWFIZnlBZDMxbE9YUzR6c1g2OEtpVUdJWXMyNUZuSW5qS3pucDJDOThjdG1ENlc4Zmt5WE9BUmtmekxhdG9ZRXhPTk9DaHc3V2xiYkl3UF81Q0J4QkhBUVhVT1Vsbks5NGFrejFWMjVFZkdqQ3ZFS1FDaGhtVmI2SmE5bVpSdFMtV2dDU2lB?oc=5","date":"2024-02-14","type":"pipeline","source":"Reuters","summary":"Cholera vaccine stocks 'empty' as cases surge - Reuters","headline":"Cholera vaccine stocks 'empty' as cases surge","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-05-16","type":"pipeline","source":"ET HealthWorld","summary":"TechInvention Lifecare, Eubiologics launch oral cholera vaccine, Euvichol-Plus in India - ET HealthWorld","headline":"TechInvention Lifecare, Eubiologics launch oral cholera vaccine, Euvichol-Plus in India","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE5uTER3NTRLejg4TnpyZTI0dWJQSnhoMnNpa3ktQ2lqZ2hBTEpxTnFvdWRkSVNXYjdIeHM0SW84bUJmWHMxaXk1Sl9ORmJSUzc5OFJ4ZHFjam9NUkNGTEs1c29BbUpYNklzUzRj?oc=5","date":"2019-02-27","type":"pipeline","source":"Allied Market Research","summary":"Cholera Vaccine Market Size, Share & Growth Report, 2025 - Allied Market Research","headline":"Cholera Vaccine Market Size, Share & Growth Report, 2025","sentiment":"neutral"}],"patents":[],"drugCount":7,"phaseCounts":{"phase_3":5,"phase_1":2},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}